Bristol Myers invests $35M into Immatics; FibroGen names new CEO

Bristol Myers Squib has made a $35 million investment into the T cell-focused biotech Immatics, purchasing over 2.4 million shares.

The move will allow for Bristol Myers to appoint someone to Immatics’ scientific advisory board. But no names were immediately brought forward, and no indications for what the funds will…
Click here to view original post